Showing results (101-110 of 112) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaXinan Sheng, Xieqiao Yan, Lin Wang, et al.Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical TrialsXinan Sheng, Lin Wang, Zhisong He, et al.The New England Journal of Medicine|October 15, 2025
A Phase 3 Trial of Telitacicept for Systemic Lupus ErythematosusRonald F van Vollenhoven, Li Wang, Joan T Merrill, et al.Cancer Research|April 29, 2025
Perivascular Niche-Resident Alveolar Macrophages Promote Interstitial Pneumonitis Related to Trastuzumab Deruxtecan TreatmentQing Wei, Teng Yang, Ziwen Zhang, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 4, 2021
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumorsYingying Xu, Yakun Wang, Jifang Gong, et al.Kidney International Reports|March 20, 2023
Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent ProteinuriaJicheng Lv, Lijun Liu, Chuanming Hao, et al.European Journal of Neurology|May 10, 2024
A multicenter, randomized, open-label, phase 2 clinical study of telitacicept in adult patients with generalized myasthenia gravisJian Yin, Mingming Zhao, Xianhao Xu, et al.Annals of the Rheumatic Diseases|December 21, 2023
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trialDi Wu, Jing Li, Dong Xu, et al.The New England Journal of Medicine|October 22, 2025
Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial CancerXinan Sheng, Gongqian Zeng, Cuijian Zhang, et al.Pageof 12